RootsAnalysis (1)

1
Liquid Biopsy and Other Non-Invasive Cancer
Diagnostics Market (3rd Edition), 2019-2030
Focus on Circulating Tumor Markers such as CTCs,
ctDNA, cfDNA, Exosomes and Other Biomarkers

• Roots Analysis

https//www.rootsanalysis.com/reports/view_documen
t/human-microbiome-market/281.html https//www.roo
tsanalysis.com/reports
2
Overview

• Cancer is known to be one of the leading causes
  of death worldwide. In 2019, 0.6 million deaths
  due to cancer are estimated in the US alone.
  Moreover, the World Health Organization has
  estimated the number of new cancer cases to rise
  by 70 over the next 20 years. One of the
  primary reasons for the high mortality associated
  with this condition is believed to be late
  diagnosis. This results in delayed treatment,
  which severely compromises chances of survival.
  For many years, tissue biopsy has been considered
  the gold standard for cancer diagnosis. However,
  owing to the invasive nature of the test,
  biopsies cannot be repeated frequently to assess
  / measure disease progression or monitor
  therapeutic outcome. In fact, in some cases, it
  is not possible to carry out a biopsy because the
  affected tissue / organ is not amenable to
  undergo such a painful and traumatic procedure.
  This has resulted in a significant unmet need for
  safer and more patient friendly cancer
  diagnostics that are capable of offering accurate
  test results.
• Advances in the field of biotechnology have
  enabled the establishment of several minimally
  invasive / non-invasive approaches for disease
  diagnosis. Amongst other promising diagnostic
  tools, liquid biopsy has emerged as a versatile
  and promising non-invasive cancer diagnostic
  tool. This procedure is based on the analysis of
  biofluids (such as blood, urine and / or plasma)
  in order to detect rare forms of biomarkers /
  tumor markers, such as circulating tumor cells
  (CTCs), circulating tumor DNA / RNA (ctNAs),
  circulating free DNA (cfDNA) and exosomes.
  Moreover, liquid biopsies have been demonstrated
  to be capable of assessing the stage of tumor at
  the time of sample extraction. Additionally,
  owing to the non-invasive nature of the test, it
  can be actively used to monitor / track changes
  in tumors, both before and during the course of
  treatment. Other than liquid biopsy, the cancer
  diagnostics market has witnessed the emergence of
  several other non-invasive diagnostic
  technologies, which are based on analytes that
  are either superficially located (such as skin
  lesions) and / or are expelled from the body
  (such as bronchial fluids and exhaled breath).
  Most of the non-invasive diagnostic techniques
  mentioned above are backed by clinical data,
  validating their relevance and applicability
  across several types of solid tumors (such as
  breast cancer, lung cancer, ovarian cancer and
  pancreatic cancer) and hematological malignancies
  (such as leukemia and lymphoma). In future,
  non-invasive cancer diagnosis methods,
  particularly liquid biopsies, are anticipated to
  replace the existing invasive diagnostic
  techniques.

3
Scope of the Report

• The 'Liquid Biopsy and Other Non-Invasive Cancer
  Diagnostics Market (3rd Edition), 2019-2030
  Focus on Circulating Tumor Markers such as CTCs,
  ctDNA, cfDNA, Exosomes and Other Biomarkers'
  report provides an extensive study on liquid
  biopsy kits / assays that are either
  commercialized or are under development for
  diagnosis and / or monitoring of different types
  of cancer. In addition, it features an elaborate
  discussion on the likely future opportunity
  associated with such tests, over the next 10
  years. Amongst other elements, the report
  includes
• A detailed review of the overall landscape of the
  non-invasive cancer diagnostics market, featuring
  information on the developers of such products
  and analyses based on a number of relevant
  parameters, such as year of establishment,
  company size, geographical location, current
  development status of proprietary liquid biopsy
  test (under development, research use only, and
  available), type of product (assay kit, software
  / algorithm and device), type of tumor marker
  analyzed (CTCs, ctDNA, cfDNA, exosomes, and
  others), key applications (early diagnosis,
  treatment selection, patient monitoring and
  recurrence monitoring), type of analyte used
  (blood, urine and others) and target cancer
  indications.
• An analysis of the various partnerships
  pertaining to non-invasive cancer diagnostics,
  which have been established between 2016 and
  2019, based on various parameters, such as type
  of partnership, year of partnership, type of
  tumor marker, target cancer indications and the
  most active players.
• An analysis of the investments made in companies
  engaged in the development of non-invasive cancer
  diagnostics, including details of seed financing,
  venture capital financing, debt financing,
  grants, and capital raised via IPOs and
  subsequent public offerings.

4
(No Transcript)
5

• One of the key objectives of the report was to
  estimate the existing market size and potential
  future growth opportunities for non-invasive
  cancer diagnostics. Based on various parameters,
  such as number of available / under development
  products and estimated annual adoption rates, we
  have provided an informed estimate on the likely
  evolution of the market over the period
  2019-2030. The report also features the likely
  distribution of the current and forecasted
  opportunity across A type of tumor marker
  (ctDNA, cfDNA, CTCs, exosomes, and others), B
  key applications (early diagnosis, patient
  monitoring and recurrence monitoring), C target
  disease indications (breast cancer, lung cancer,
  colorectal cancer, prostate cancer, bladder
  cancer, melanoma, gastric cancer, pancreatic
  cancer, ovarian cancer, and others), D end
  users (hospitals, research institutes and
  others), and E key geographical regions (the
  US, the UK, Germany, Italy, Spain, France, Japan,
  Australia, China, India, and rest of the world).
  In order to account for future uncertainties and
  to add robustness to our model, we have provided
  three market forecast scenarios, namely
  conservative, base and optimistic scenarios,
  representing different tracks of the industrys
  growth.
• The opinions and insights presented in the report
  were influenced by discussions held with senior
  stakeholders in the industry. The report features
  detailed transcripts of interviews held with the
  following industry stakeholders
• Shibichakravarthy Kannan, Founder and CEO,
  Theranosis Life Sciences
• Abizar Lakdawalla, Founder, ProXeom
• Philippe Nore, CEO and Co-founder, MiNDERA
  Corporation
• Frank Szczepanski, President and CEO,
  IVDiagnostics
• Mark Li, CEO, Resolution Bioscience
• Brad Walsh, CEO, Minomic International
• Joachim Fluhrer, Founder and Medical Director,
  Genostics
• Anton Iliuk, President and Chief Technology
  Officer, Tymora Analytical Oper

6

• Contents
• Chapter Outlines
• Chapter 2 provides an executive summary of the
  insights captured in our research. It offers a
  high-level view on the current scenario within
  the liquid biopsy market and describes its
  evolution in the short-mid term and long term.
• Chapter 3 provides an overview of cancer
  statistics and the global burden of the disease.
  In this section of the report, we have also
  highlighted the importance of early detection of
  the disease through diagnosis and asymptomatic
  screening. The chapter outlines the conventional
  invasive diagnostic tests, which are widely used
  for cancer diagnosis and prognosis.
• Chapter 4 discusses, in detail, the need for
  non-invasive cancer diagnostics and their
  importance. The chapter presents the underlying
  concept of different imaging techniques,
  screening assays and advanced approaches used for
  diagnosis of cancer, highlighting the advantages
  and disadvantages of each of the aforementioned
  techniques.

7
For additional details, please visit

• https//www.rootsanalysis.com or email
  sales_at_rootsanalysis.com
• Contact
• Gaurav Chaudhary
• 1 [phone]
• 44 [phone]
• Gaurav.Chaudhary_at_rootsanalysis.com
• https//www.rootsanalysis.com/reports
• https//www.rootsanalysis.com/press-releases.html